Removal of mexiletine’s off-target effects against IKr, has been the subject of recent research to improve mexiletine as a selective therapy for LQT3 patients40, and our data suggest that this selectivity will also benefit NAA10-syndrome patients. The gene discussed is NAA10; the disease is Down syndrome.